tamsulosin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	2562	106133-20-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: tamsulosin tamsulosin hydrochloride tamsulosin HCl LY-253352	A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA. Molecular weight: 408.51 Formula: C20H28N2O5S CLOGP: 2.17 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 99.88 ALOGS: -4.79 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

tamsulosin
tamsulosin hydrochloride
tamsulosin HCl
LY-253352

A sulfonamide derivative and adrenergic alpha-1 receptor antagonist that is used to relieve symptoms of urinary obstruction caused by BENIGN PROSTATIC HYPERPLASIA.

Molecular weight: 408.51
Formula: C20H28N2O5S
CLOGP: 2.17
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 99.88
ALOGS: -4.79
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8.70 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.03 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.21 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.62 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	6.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 15, 1997	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrolithiasis	149.37	15.47	80	6783	32971	46646228
Urinary tract infection	78.23	15.47	126	6737	220140	46459059
Multiple sclerosis relapse	71.49	15.47	55	6808	42070	46637129
Urinary retention	55.42	15.47	39	6824	26022	46653177
Residual urine volume increased	45.87	15.47	7	6856	18	46679181
Ligament pain	32.15	15.47	7	6856	171	46679028
Respiratory tract inflammation	30.35	15.47	8	6855	447	46678752
Renal colic	30.03	15.47	10	6853	1256	46677943
Rheumatoid arthritis	24.99	15.47	3	6860	240212	46438987
Progressive multifocal leukoencephalopathy	24.15	15.47	17	6846	11329	46667870
Pertussis	23.73	15.47	7	6856	591	46678608
Multiple sclerosis	23.05	15.47	23	6840	24768	46654431
Chorioretinitis	22.94	15.47	6	6857	325	46678874
Sinus pain	22.49	15.47	9	6854	1901	46677298
Disorganised speech	21.14	15.47	7	6856	864	46678335
Drug ineffective	20.74	15.47	43	6820	677795	46001404
Iris disorder	19.70	15.47	4	6859	69	46679130
Immune reconstitution inflammatory syndrome	18.12	15.47	11	6852	5714	46673485
Renal stone removal	17.85	15.47	4	6859	112	46679087
Hypertensive nephropathy	17.29	15.47	5	6858	394	46678805
Urinary tract obstruction	16.43	15.47	7	6856	1731	46677468
Product use issue	16.21	15.47	40	6823	94604	46584595
Central nervous system stimulation	16.11	15.47	3	6860	32	46679167
Erythropenia	15.70	15.47	4	6859	195	46679004

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Iris disorder	745.02	10.46	201	150714	163	29801400
Urinary retention	380.06	10.46	632	150283	32285	29769278
Dizziness	322.32	10.46	1875	149040	193034	29608529
Fall	308.08	10.46	1761	149154	180111	29621452
Cataract operation complication	257.21	10.46	73	150842	86	29801477
Syncope	243.90	10.46	959	149956	83944	29717619
Orthostatic hypotension	240.85	10.46	433	150482	23546	29778017
Drug abuse	223.16	10.46	68	150847	82004	29719559
Iridocele	220.91	10.46	57	150858	30	29801533
Urinary tract infection	194.75	10.46	811	150104	72848	29728715
Toxicity to various agents	189.04	10.46	380	150535	176803	29624760
Floppy iris syndrome	169.36	10.46	63	150852	258	29801305
Procedural complication	165.77	10.46	155	150760	4342	29797221
Completed suicide	133.21	10.46	184	150731	99308	29702255
Dysuria	132.53	10.46	327	150588	22214	29779349
Idiopathic pulmonary fibrosis	125.15	10.46	127	150788	3942	29797621
Benign prostatic hyperplasia	118.36	10.46	199	150716	10248	29791315
Pollakiuria	108.79	10.46	254	150661	16652	29784911
Product prescribing error	93.38	10.46	238	150677	16495	29785068
Prostatomegaly	90.10	10.46	114	150801	4522	29797041
Retrograde ejaculation	83.81	10.46	38	150877	281	29801282
Haematuria	82.77	10.46	445	150470	44389	29757174
Asthenia	81.62	10.46	1566	149349	219724	29581839
Off label use	76.66	10.46	845	150070	248445	29553118
Multiple organ dysfunction syndrome	76.61	10.46	126	150789	63361	29738202
Urinary incontinence	74.67	10.46	221	150694	16719	29784844
Nocturia	74.52	10.46	143	150772	8169	29793394
Pupillary disorder	73.78	10.46	32	150883	210	29801353
Fatigue	70.26	10.46	2112	148803	318561	29483002
Urine flow decreased	69.22	10.46	53	150862	1119	29800444
Atrial fibrillation	67.51	10.46	837	150078	107287	29694276
Drug resistance	66.03	10.46	11	150904	20122	29781441
Intentional overdose	65.85	10.46	67	150848	41414	29760149
Micturition urgency	63.86	10.46	94	150821	4313	29797250
Prostate cancer	63.38	10.46	264	150651	23693	29777870
Presyncope	62.88	10.46	201	150714	15855	29785708
Drug ineffective	62.36	10.46	1276	149639	339111	29462452
Prostatic disorder	61.58	10.46	73	150842	2705	29798858
Miosis	61.56	10.46	127	150788	7649	29793914
Febrile neutropenia	61.04	10.46	303	150612	106390	29695173
Hallucination	57.04	10.46	433	150482	48626	29752937
Hypotension	56.98	10.46	1367	149548	199198	29602365
Prostatic specific antigen increased	56.17	10.46	160	150755	11844	29789719
Cytomegalovirus infection	55.25	10.46	25	150890	23649	29777914
Product monitoring error	54.75	10.46	55	150860	1686	29799877
Drug dependence	53.72	10.46	20	150895	21275	29780288
Cardio-respiratory arrest	51.18	10.46	135	150780	57171	29744392
Confusional state	50.19	10.46	956	149959	133878	29667685
Suicide attempt	49.93	10.46	67	150848	36630	29764933
Abdominal pain lower	46.88	10.46	123	150792	8675	29792888
Respiratory arrest	46.72	10.46	47	150868	29211	29772352
Pyrexia	46.41	10.46	1130	149785	293359	29508204
Overdose	45.68	10.46	244	150671	84093	29717470
Treatment failure	45.49	10.46	65	150850	34614	29766949
Balance disorder	45.20	10.46	327	150588	36166	29765397
Drug reaction with eosinophilia and systemic symptoms	44.09	10.46	47	150868	28441	29773122
Product substitution issue	43.35	10.46	130	150785	9905	29791658
Lower urinary tract symptoms	42.54	10.46	19	150896	135	29801428
Ocular procedural complication	41.82	10.46	15	150900	54	29801509
Ejaculation failure	40.49	10.46	33	150882	765	29800798
Labelled drug-drug interaction medication error	40.42	10.46	131	150784	10407	29791156
Bladder cancer	40.35	10.46	119	150796	8983	29792580
Alanine aminotransferase increased	40.16	10.46	215	150700	74061	29727502
Cystitis	38.58	10.46	111	150804	8263	29793300
Loss of consciousness	38.30	10.46	587	150328	78788	29722775
Bladder disorder	37.14	10.46	58	150857	2805	29798758
Rheumatoid arthritis	36.06	10.46	98	150817	41099	29760464
Cardiac arrest	35.98	10.46	297	150618	92553	29709010
Nephrolithiasis	35.89	10.46	231	150684	24579	29776984
Leukopenia	35.33	10.46	154	150761	56005	29745558
Bradycardia	35.32	10.46	494	150421	65032	29736531
Muscular weakness	35.19	10.46	482	150433	63163	29738400
Cataract operation	35.11	10.46	36	150879	1131	29800432
Cataract	34.53	10.46	208	150707	21627	29779936
Dacryocystitis	34.37	10.46	8	150907	0	29801563
Dyspnoea	34.34	10.46	2028	148887	331267	29470296
Bone marrow failure	34.18	10.46	61	150854	29724	29771839
Memory impairment	34.05	10.46	311	150604	36863	29764700
Gait disturbance	33.80	10.46	547	150368	74230	29727333
Bladder spasm	33.78	10.46	31	150884	847	29800716
Peritonitis	33.38	10.46	35	150880	21340	29780223
Prostatitis	32.96	10.46	75	150840	4832	29796731
Disseminated intravascular coagulation	32.75	10.46	38	150877	22133	29779430
Full blood count decreased	32.45	10.46	161	150754	15556	29786007
Nipple pain	32.15	10.46	26	150889	596	29800967
Constipation	32.11	10.46	770	150145	112136	29689427
Hormone receptor positive breast cancer	31.75	10.46	10	150905	21	29801542
Neutropenia	31.43	10.46	457	150458	128083	29673480
Peripheral swelling	31.14	10.46	456	150459	60618	29740945
Vitreous loss	30.51	10.46	8	150907	5	29801558
Plasmapheresis	30.23	10.46	20	150895	332	29801231
Testicular swelling	30.19	10.46	36	150879	1342	29800221
Hepatic failure	29.78	10.46	81	150834	33962	29767601
Haemophagocytic lymphohistiocytosis	28.67	10.46	7	150908	9784	29791779
Aspergillus infection	28.58	10.46	8	150907	10206	29791357
Graft versus host disease	28.31	10.46	8	150907	10142	29791421
Head injury	28.11	10.46	164	150751	16856	29784707
Product use in unapproved indication	27.51	10.46	238	150677	73455	29728108
Thrombocytopenia	27.00	10.46	507	150408	136537	29665026
Urinary tract obstruction	26.28	10.46	55	150860	3346	29798217
Myocardial infarction	26.24	10.46	460	150455	125165	29676398
Urosepsis	25.86	10.46	115	150800	10617	29790946
Septic shock	25.76	10.46	201	150714	63406	29738157
Wound	25.57	10.46	127	150788	12275	29789288
Blood urine present	25.32	10.46	108	150807	9792	29791771
Dementia	25.27	10.46	127	150788	12334	29789229
Hot flush	25.25	10.46	143	150772	14537	29787026
Bladder catheterisation	25.20	10.46	22	150893	562	29801001
Dizziness postural	25.18	10.46	73	150842	5457	29796106
Poisoning	25.06	10.46	13	150902	11369	29790194
Priapism	24.95	10.46	66	150849	4677	29796886
Intentional self-injury	24.91	10.46	19	150896	13513	29788050
General physical health deterioration	24.13	10.46	667	150248	99277	29702286
Incontinence	23.96	10.46	70	150845	5256	29796307
Immune reconstitution inflammatory syndrome	23.89	10.46	8	150907	9093	29792470
Atrial septal defect	23.50	10.46	3	150912	6698	29794865
Synovitis	23.35	10.46	10	150905	9773	29791790
Faeces discoloured	22.78	10.46	134	150781	13812	29787751
Vomiting	22.64	10.46	892	150023	218926	29582637
Factitious disorder	22.29	10.46	9	150906	48	29801515
Contusion	22.06	10.46	248	150667	31032	29770531
Coma	21.90	10.46	117	150798	40332	29761231
Thrombotic microangiopathy	21.86	10.46	8	150907	8602	29792961
Dry mouth	21.86	10.46	193	150722	22657	29778906
Bladder outlet obstruction	21.79	10.46	12	150903	140	29801423
Haematoma	21.73	10.46	200	150715	23753	29777810
Seizure	21.72	10.46	357	150558	98118	29703445
Platypnoea	21.65	10.46	8	150907	32	29801531
Mucosal inflammation	21.45	10.46	80	150835	30414	29771149
Pallor	21.29	10.46	180	150735	20869	29780694
Toxic epidermal necrolysis	21.26	10.46	36	150879	17904	29783659
Cornea verticillata	21.09	10.46	8	150907	35	29801528
Idiopathic interstitial pneumonia	20.93	10.46	11	150904	116	29801447
Oedema peripheral	20.89	10.46	689	150226	105143	29696420
Drug intolerance	20.82	10.46	138	150777	45153	29756410
Milk-alkali syndrome	20.68	10.46	19	150896	520	29801043
Perineal pain	20.67	10.46	20	150895	585	29800978
Micturition disorder	20.64	10.46	35	150880	1814	29799749
Pneumocystis jirovecii pneumonia	20.61	10.46	34	150881	17086	29784477
Vertigo	20.54	10.46	189	150726	22446	29779117
Hospice care	20.49	10.46	59	150856	4393	29797170
Bladder neck obstruction	20.30	10.46	11	150904	124	29801439
Pancreatitis	20.06	10.46	105	150810	36385	29765178
Prostatic mass	20.00	10.46	7	150908	23	29801540
Aortic stenosis	19.96	10.46	55	150860	3993	29797570
Peritonitis bacterial	19.67	10.46	17	150898	11361	29790202
Intentional product misuse	19.48	10.46	99	150816	34568	29766995
Infusion related reaction	19.46	10.46	122	150793	40442	29761121
Pathogen resistance	19.43	10.46	9	150906	8401	29793162
Agranulocytosis	19.34	10.46	52	150863	21890	29779673
Guillain-Barre syndrome	19.32	10.46	63	150852	5020	29796543
Haematochezia	19.24	10.46	260	150655	33962	29767601
Hepatotoxicity	19.21	10.46	39	150876	18106	29783457
Cytomegalovirus viraemia	19.08	10.46	3	150912	5726	29795837
Dysgeusia	19.04	10.46	200	150715	24601	29776962
Iris atrophy	19.04	10.46	9	150906	74	29801489
Stomal hernia	18.98	10.46	10	150905	106	29801457
Erectile dysfunction	18.95	10.46	156	150759	17946	29783617
Therapeutic product effect incomplete	18.80	10.46	97	150818	33737	29767826
Hepatomegaly	18.63	10.46	14	150901	10033	29791530
Brain oedema	18.58	10.46	21	150894	12377	29789186
Adverse drug reaction	18.41	10.46	188	150727	22957	29778606
Prostatic operation	18.27	10.46	14	150901	296	29801267
Acute respiratory distress syndrome	18.25	10.46	59	150856	23413	29778150
C-reactive protein increased	18.25	10.46	136	150779	43337	29758226
Transaminases increased	18.21	10.46	59	150856	23398	29778165
Periorbital haematoma	18.07	10.46	15	150900	357	29801206
Hydronephrosis	17.82	10.46	91	150824	8892	29792671
Intentional product use issue	17.79	10.46	109	150806	36331	29765232
Urinary hesitation	17.72	10.46	37	150878	2247	29799316
Palpitations	17.63	10.46	252	150663	33321	29768242
Resting tremor	17.60	10.46	18	150897	564	29800999
Iris haemorrhage	17.57	10.46	5	150910	6	29801557
Drug hypersensitivity	17.29	10.46	242	150673	68277	29733286
Ageusia	17.28	10.46	90	150825	8863	29792700
Candida infection	17.14	10.46	32	150883	15330	29786233
Aspartate aminotransferase increased	17.09	10.46	221	150694	63201	29738362
Hepatitis C	17.07	10.46	25	150890	13180	29788383
Diabetic neuropathy	16.83	10.46	51	150864	3908	29797655
Myelosuppression	16.67	10.46	8	150907	7314	29794249
Transurethral prostatectomy	16.56	10.46	14	150901	342	29801221
Hypoacusis	16.53	10.46	125	150790	14014	29787549
Stress	16.34	10.46	50	150865	20185	29781378
Metabolic acidosis	16.29	10.46	116	150799	37345	29764218
Bladder discomfort	16.19	10.46	9	150906	107	29801456
Back pain	16.11	10.46	651	150264	101945	29699618
Urinary tract disorder	16.10	10.46	33	150882	1978	29799585
Post micturition dribble	16.04	10.46	5	150910	10	29801553
Osteonecrosis	15.98	10.46	36	150879	16099	29785464
Prostate cancer metastatic	15.96	10.46	59	150856	5008	29796555
Dacryostenosis acquired	15.93	10.46	10	150905	151	29801412
Hepatocellular injury	15.92	10.46	70	150845	25401	29776162
Taste disorder	15.88	10.46	46	150869	3437	29798126
Angle closure glaucoma	15.79	10.46	19	150896	715	29800848
Blood bilirubin increased	15.67	10.46	114	150801	36522	29765041
Megakaryocytes increased	15.64	10.46	7	150908	50	29801513
Dysphagia	15.59	10.46	385	150530	56313	29745250
Urinary bladder haemorrhage	15.54	10.46	29	150886	1622	29799941
Subdural haematoma	15.52	10.46	155	150760	18817	29782746
Hepatitis	15.50	10.46	59	150856	22297	29779266
Hypertriglyceridaemia	15.39	10.46	11	150904	8087	29793476
Puncture site haematoma	15.27	10.46	10	150905	163	29801400
Tendon pain	15.21	10.46	37	150878	2490	29799073
Bronchopulmonary aspergillosis	15.16	10.46	24	150891	12260	29789303
Prostatism	15.14	10.46	12	150903	267	29801296
Post transplant lymphoproliferative disorder	15.14	10.46	4	150911	5302	29796261
Hip fracture	15.13	10.46	102	150813	11022	29790541
Pancytopenia	15.12	10.46	320	150595	84732	29716831
Burning feet syndrome	15.01	10.46	8	150907	87	29801476
Sperm concentration zero	14.96	10.46	4	150911	3	29801560
Bovine tuberculosis	14.92	10.46	9	150906	126	29801437
Executive dysfunction	14.92	10.46	9	150906	126	29801437
Breast disorder male	14.87	10.46	5	150910	14	29801549
Cystitis haemorrhagic	14.87	10.46	3	150912	4784	29796779
Macular degeneration	14.75	10.46	32	150883	1996	29799567
Acute hepatic failure	14.70	10.46	23	150892	11804	29789759
Arteriovenous fistula	14.68	10.46	17	150898	614	29800949
Gallbladder hypofunction	14.62	10.46	5	150910	15	29801548
Prostatic obstruction	14.62	10.46	9	150906	131	29801432
Gait inability	14.49	10.46	152	150763	18689	29782874
Stevens-Johnson syndrome	14.45	10.46	43	150872	17513	29784050
Myxoedema coma	14.44	10.46	12	150903	286	29801277
Hepatic enzyme increased	14.43	10.46	104	150811	33390	29768173
Diabetes mellitus	14.40	10.46	138	150777	41727	29759836
Benign gastrointestinal neoplasm	14.39	10.46	9	150906	135	29801428
Transient ischaemic attack	14.39	10.46	192	150723	25008	29776555
Suprapubic pain	14.33	10.46	13	150902	350	29801213
Hyponatraemic syndrome	14.30	10.46	11	150904	234	29801329
Psoriasis	14.25	10.46	141	150774	42365	29759198
Breast tenderness	14.22	10.46	18	150897	714	29800849
Muscle spasms	14.06	10.46	427	150488	64411	29737152
Tuberculosis	14.04	10.46	12	150903	8065	29793498
Paraplegia	13.97	10.46	37	150878	2624	29798939
Loss of bladder sensation	13.90	10.46	7	150908	67	29801496
Product prescribing issue	13.89	10.46	19	150896	814	29800749
Renal tubular disorder	13.86	10.46	4	150911	5002	29796561
Urogenital disorder	13.75	10.46	6	150909	40	29801523
Haematotoxicity	13.65	10.46	7	150908	6163	29795400
Mydriasis	13.55	10.46	7	150908	6136	29795427
Blood pressure systolic	13.55	10.46	4	150911	6	29801557
Metastases to neck	13.55	10.46	4	150911	6	29801557
Dysstasia	13.50	10.46	95	150820	10410	29791153
Arteriosclerotic gangrene	13.47	10.46	7	150908	72	29801491
Herpes simplex	13.45	10.46	3	150912	4461	29797102
Intestinal haemorrhage	13.38	10.46	41	150874	3160	29798403
Status epilepticus	13.32	10.46	22	150893	11050	29790513
Daydreaming	13.25	10.46	14	150901	456	29801107
Wrong schedule	13.20	10.46	8	150907	113	29801450
Calculus bladder	13.12	10.46	19	150896	859	29800704
Hepatic steatosis	13.08	10.46	35	150880	14758	29786805
Serum ferritin abnormal	13.06	10.46	10	150905	211	29801352
Testicular pain	13.02	10.46	37	150878	2735	29798828
Ascites	12.96	10.46	117	150798	35804	29765759
Psychotic disorder	12.92	10.46	60	150855	21455	29780108
Lymphadenopathy	12.92	10.46	71	150844	24305	29777258
Prostatic acid phosphatase increased	12.89	10.46	3	150912	0	29801563
Pupillary block	12.89	10.46	3	150912	0	29801563
Iris injury	12.89	10.46	3	150912	0	29801563
Hyponatraemia	12.86	10.46	436	150479	66766	29734797
Acidosis	12.83	10.46	20	150895	10281	29791282
Respiratory depression	12.80	10.46	24	150891	11479	29790084
Breast enlargement	12.74	10.46	13	150902	406	29801157
Tubulointerstitial nephritis	12.54	10.46	47	150868	17844	29783719
Oesophageal rupture	12.54	10.46	13	150902	414	29801149
Lymphopenia	12.53	10.46	30	150885	13133	29788430
Pain in extremity	12.50	10.46	677	150238	109544	29692019
Flatulence	12.45	10.46	143	150772	17986	29783577
Frostbite	12.42	10.46	6	150909	52	29801511
Femoral artery aneurysm	12.34	10.46	9	150906	176	29801387
Dental restoration failure	12.33	10.46	5	150910	27	29801536
Choroidal detachment	12.26	10.46	12	150903	356	29801207
Phaeochromocytoma malignant	12.23	10.46	6	150909	54	29801509
Invasive ductal breast carcinoma	12.22	10.46	4	150911	10	29801553
Lichen sclerosus	12.22	10.46	4	150911	10	29801553
Pharyngeal cancer	12.18	10.46	5	150910	28	29801535
Product use issue	12.15	10.46	161	150754	45855	29755708
Food aversion	12.13	10.46	11	150904	296	29801267
Hepatic function abnormal	12.11	10.46	144	150771	41801	29759762
Neurogenic bladder	12.08	10.46	26	150889	1613	29799950
Psoriatic arthropathy	11.99	10.46	40	150875	15721	29785842
Lip swelling	11.86	10.46	107	150808	12637	29788926
Haematospermia	11.81	10.46	12	150903	373	29801190
Urethral pain	11.76	10.46	5	150910	31	29801532
Haemorrhage urinary tract	11.76	10.46	26	150889	1643	29799920
Posterior reversible encephalopathy syndrome	11.73	10.46	16	150899	8691	29792872
Chronic obstructive pulmonary disease	11.73	10.46	310	150605	45816	29755747
Blood creatine phosphokinase increased	11.73	10.46	153	150762	43695	29757868
Rectal haemorrhage	11.71	10.46	244	150671	34695	29766868
Cytokine release syndrome	11.71	10.46	20	150895	9913	29791650
Bedridden	11.70	10.46	43	150872	3639	29797924
Hypertonic bladder	11.67	10.46	18	150897	861	29800702
Hepatocellular carcinoma	11.65	10.46	19	150896	9591	29791972
Pulmonary tuberculosis	11.53	10.46	5	150910	4852	29796711
Drug withdrawal syndrome	11.45	10.46	56	150859	19753	29781810
Iris adhesions	11.44	10.46	9	150906	198	29801365
Colitis ulcerative	11.42	10.46	36	150879	14398	29787165
Multiple system atrophy	11.40	10.46	9	150906	199	29801364
Cerebral haematoma	11.36	10.46	49	150866	4465	29797098
Subdural hygroma	11.34	10.46	11	150904	323	29801240
Extrapyramidal disorder	11.30	10.46	23	150892	10670	29790893
Drug dispensed to wrong patient	11.30	10.46	8	150907	149	29801414
Akathisia	11.24	10.46	8	150907	5896	29795667
Bladder pain	11.23	10.46	12	150903	396	29801167
Faecaloma	11.22	10.46	48	150867	4357	29797206
Nephropathy toxic	11.15	10.46	23	150892	10616	29790947
Therapy non-responder	11.04	10.46	95	150820	29358	29772205
Hypoxia	11.03	10.46	172	150743	47682	29753881
Blood loss anaemia	11.02	10.46	71	150844	7556	29794007
Gynaecomastia	11.02	10.46	76	150839	8275	29793288
Visual impairment	11.01	10.46	215	150700	30223	29771340
Blood glucose fluctuation	11.01	10.46	42	150873	3619	29797944
Wound haematoma	10.97	10.46	6	150909	69	29801494
Bulbar palsy	10.92	10.46	9	150906	212	29801351
Bladder obstruction	10.91	10.46	14	150901	563	29801000
Urinary retention postoperative	10.89	10.46	6	150909	70	29801493
Hepatic necrosis	10.86	10.46	3	150912	3860	29797703
Atrioventricular block first degree	10.85	10.46	57	150858	5631	29795932
Inadequate osteointegration	10.83	10.46	4	150911	16	29801547
Electrocardiogram RR interval prolonged	10.82	10.46	3	150912	3	29801560
Anorectal operation	10.82	10.46	3	150912	3	29801560
Respiratory distress	10.79	10.46	110	150805	32862	29768701
Radiation inflammation	10.75	10.46	7	150908	113	29801450
Skin laceration	10.74	10.46	95	150820	11156	29790407
Electrocardiogram QT prolonged	10.74	10.46	122	150793	35713	29765850
Sinus tachycardia	10.69	10.46	41	150874	15463	29786100
Renal haematoma	10.63	10.46	13	150902	498	29801065
Palatal oedema	10.55	10.46	16	150899	754	29800809
Halo vision	10.52	10.46	8	150907	167	29801396
International normalised ratio increased	10.51	10.46	315	150600	47424	29754139
Spinal fracture	10.49	10.46	64	150851	6684	29794879
Blood pressure decreased	10.47	10.46	311	150604	46764	29754799
Substance abuse	10.47	10.46	12	150903	7028	29794535

Pharmacologic Action:

Source	Code	Description
ATC	G04CA02	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA52	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA53	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA54	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:35610	cytostatic
CHEBI has role	CHEBI:37890	alpha-adrenoceptor antagonists

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Benign prostatic hyperplasia	indication	266569009
Priapism	contraindication	6273006	DOID:9286
Orthostatic hypotension	contraindication	28651003
Oligozoospermia	contraindication	88311004
Cataract surgery	contraindication	110473004
Disease of liver	contraindication	235856003	DOID:409
Syncope	contraindication	271594007
Pregnancy, function	contraindication	289908002
Dizziness	contraindication	404640003
Breastfeeding (mother)	contraindication	413712001
Intraoperative floppy iris syndrome	contraindication	418801006
High-Grade Prostate Cancer	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.71	acidic
pKa2	8.16	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN	Ki	9.10	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	Ki	7.87	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	Ki	7.89	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	Ki	10.24	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	Ki	10.54	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	Ki	9.21	CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	Ki	9.55	CHEMBL
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	Ki	8.10	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN	Ki	7.08	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_MESAU	Ki	9.70	CHEMBL
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT	Ki	8.17	CHEMBL
Alpha-1D adrenergic receptor	GPCR		ADA1D_RAT	Ki	10.15	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT	Ki	10.52	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT	Ki	6.03	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN	Ki	9.90	CHEMBL

External reference:

ID	Source
4024076	VUID
N0000022081	NUI
D01024	KEGG_DRUG
106463-17-6	SECONDARY_CAS_RN
4021051	VANDF
4024076	VANDF
C0636157	UMLSCUI
CHEBI:9398	CHEBI
CHEMBL836	ChEMBL_ID
CHEMBL1200914	ChEMBL_ID
D000077409	MESH_DESCRIPTOR_UI
6750	INN_ID
DB00706	DRUGBANK_ID
G3P28OML5I	UNII
6917671	PUBCHEM_CID
488	IUPHAR_LIGAND_ID
236495	RXNORM
171693	MMSL
20642	MMSL
5541	MMSL
d04121	MMSL
006115	NDDF
006116	NDDF
108559004	SNOMEDCT_US
108560009	SNOMEDCT_US
372509005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FLOMAX	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5837	CAPSULE	0.40 mg	ORAL	NDA	30 sections
JALYN	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0809	CAPSULE	0.40 mg	ORAL	NDA	29 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2996	CAPSULE	0.40 mg	ORAL	ANDA	19 sections
Flomax	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0058	CAPSULE	0.40 mg	ORAL	NDA	27 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7995	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8055	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2076	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6401	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10370-169	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
Dutasteride and Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	10370-280	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-280	CAPSULE	0.40 mg	ORAL	ANDA	18 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10544-550	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-298	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
FLOMAX	HUMAN PRESCRIPTION DRUG LABEL	1	16590-489	CAPSULE	0.40 mg	ORAL	NDA	28 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	16714-713	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-839	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	33342-159	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42254-012	CAPSULE	0.40 mg	ORAL	ANDA	17 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-264	CAPSULE	0.40 mg	ORAL	ANDA	19 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-725	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43063-947	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-013	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	43353-019	CAPSULE	0.40 mg	ORAL	ANDA	26 sections
Tamsulosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-663	CAPSULE	0.40 mg	ORAL	ANDA	19 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-1846	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-3646	CAPSULE	0.40 mg	ORAL	ANDA	29 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50090-4906	CAPSULE	0.40 mg	ORAL	ANDA	29 sections
Tamsulosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-740	CAPSULE	0.40 mg	ORAL	ANDA	30 sections
Tamsulosin Hydrochloride	Human Prescription Drug Label	1	50436-0598	CAPSULE	0.40 mg	ORAL	ANDA	27 sections
TAMSULOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51655-677	CAPSULE	0.40 mg	ORAL	ANDA	14 sections